☰

cached image

Hiroshi Yamazaki - Publications

Affiliations: 
Showa Pharmaceutical University 
Area:
drug metabolism
Website:
http://orcid.org/0000-0002-1068-4261
Tree Info Similar researchers PubMed Report error

319 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Shimizu M, Uno Y, Utoh M, Yamazaki H. Trimethylamine N-oxygenation in cynomolgus macaques genotyped for flavin-containing monooxygenase 3 (FMO3). Drug Metabolism and Pharmacokinetics. PMID 32967780 DOI: 10.1016/J.Dmpk.2020.07.001  0.322
2020 Ito S, Kamimura H, Yamamoto Y, Chijiwa H, Okuzono T, Suemizu H, Yamazaki H. Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling. Drug Metabolism and Pharmacokinetics. PMID 32962912 DOI: 10.1016/J.Dmpk.2020.07.004  0.314
2020 Uno Y, Mikami T, Tsukazaki Y, Nakanishi Y, Murayama N, Ikushiro S, Tsusaki H, Yamazaki H. Genetic variants of UDP-glucuronosyltransferases 1A1, 1A6, and 1A9 in cynomolgus and rhesus macaques. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-7. PMID 32811258 DOI: 10.1080/00498254.2020.1810367  0.317
2020 Uehara S, Uno Y, Yamazaki H. Molecular cloning and tissue distribution of marmoset thiopurine S-methyltransferase. Drug Metabolism and Pharmacokinetics. PMID 32788077 DOI: 10.1016/J.Dmpk.2020.06.001  0.308
2020 Uehara S, Uno Y, Yamazaki H. Molecular cloning, sequence analysis, and tissue distribution of marmoset monoamine oxidases A and B. Drug Metabolism and Pharmacokinetics. PMID 32782138 DOI: 10.1016/J.Dmpk.2020.06.002  0.303
2020 Uno Y, Uehara S, Murayama N, Shimizu M, Yamazaki H. Expression of functional sulfotransferases (SULT) 1A1, 1A3, 1B1, 1C2, 1E1, and 2A1 in common marmosets. Biochemical Pharmacology. 180: 114189. PMID 32768400 DOI: 10.1016/J.Bcp.2020.114189  0.34
2020 Nakanishi Y, Uno Y, Yamazaki H. Regional distributions of UDP-glucuronosyltransferase activities toward estradiol and serotonin in the liver and small intestine of cynomolgus macaques. Drug Metabolism and Pharmacokinetics. 35: 401-404. PMID 32651149 DOI: 10.1016/J.Dmpk.2020.05.005  0.322
2020 Uno Y, Yamazaki H. Molecular characterization of UDP-glucuronosyltransferases 3A and 8A in cynomolgus macaques. Drug Metabolism and Pharmacokinetics. 35: 397-400. PMID 32646660 DOI: 10.1016/J.Dmpk.2020.05.001  0.354
2020 Ogawa SI, Shimizu M, Yamazaki H. Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-10. PMID 32628085 DOI: 10.1080/00498254.2020.1793030  0.34
2020 Ogawa SI, Shimizu M, Kamiya Y, Uehara S, Suemizu H, Yamazaki H. Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1. Drug Metabolism and Pharmacokinetics. PMID 32601018 DOI: 10.1016/J.Dmpk.2020.03.005  0.315
2020 Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. Human Aldehyde Oxidase 1-mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 32357972 DOI: 10.1124/Dmd.120.091090  0.325
2020 Uno Y, Murayama N, Yamazaki H. Genetic variants of N-acetyltransferases 1 and 2 (NAT1 and NAT2) in cynomolgus and rhesus macaques. Biochemical Pharmacology. 113996. PMID 32339492 DOI: 10.1016/J.Bcp.2020.113996  0.344
2020 Nagayoshi H, Murayama N, Tsujino M, Takenaka S, Katahira J, Kim V, Kim D, Komori M, Yamazaki H, Guengerich FP, Shimada T. Preference for -demethylation reactions in the oxidation of 2´-, 3´-, and 4´-methoxyflavones by human cytochrome P450 enzymes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-42. PMID 32312164 DOI: 10.1080/00498254.2020.1759157  0.312
2020 Uno Y, Murayama N, Yamazaki H. Interleukin-1β and tumor necrosis factor-α affect cytochrome P450 expression in cynomolgus macaque hepatocytes. Drug Metabolism and Pharmacokinetics. PMID 32253084 DOI: 10.1016/J.Dmpk.2020.02.001  0.321
2020 Uno Y, Uehara S, Tanaka S, Murayama N, Yamazaki H. Systematic characterization of glutathione S-transferases in common marmosets. Biochemical Pharmacology. 113835. PMID 32027883 DOI: 10.1016/J.Bcp.2020.113835  0.325
2020 Ogawa SI, Shimizu M, Yamazaki H. Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-9. PMID 31900032 DOI: 10.1080/00498254.2019.1709133  0.304
2020 Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. P119 - Drug-metabolizing activity and cytochromes P450 induction in human hepatocytes from TK-NOG chimeric mice with humanized livers Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.120  0.368
2020 Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. P39 - Metabolism of desloratadine in TK-NOG chimeric mice with humanized livers Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.040  0.334
2019 Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Cloning and tissue expression of cytochrome P450 2S1, 4V2, 7A1, 7B1, 8B1, 24A1, 26A1, 26C1, 27A1, 39A1, and 51A1 in marmosets. Drug Metabolism and Pharmacokinetics. PMID 31980379 DOI: 10.1016/J.Dmpk.2019.11.008  0.323
2019 Uno Y, Yamazaki H. mRNA levels of drug-metabolizing enzymes in 11 brain regions of cynomolgus macaques. Drug Metabolism and Pharmacokinetics. PMID 31964621 DOI: 10.1016/J.Dmpk.2019.12.003  0.315
2019 Miura T, Uehara S, Shimizu M, Murayama N, Utoh M, Suemizu H, Yamazaki H. Different roles of human cytochrome P450 2C9 and 3A enzymes in diclofenac 4'- and 5-hydroxylations mediated by metabolically inactivated human hepatocytes in previously transplanted chimeric mice. Chemical Research in Toxicology. PMID 31854189 DOI: 10.1021/Acs.Chemrestox.9B00446  0.364
2019 Uno Y, Uehara S, Inoue T, Kawamura S, Murayama N, Nishikawa M, Ikushiro S, Sasaki E, Yamazaki H. Molecular characterization of functional UDP-glucuronosyltransferases 1A, 2B in common marmosets. Biochemical Pharmacology. 113748. PMID 31830470 DOI: 10.1016/J.Bcp.2019.113748  0.354
2019 Ogawa SI, Uehara S, Tsunenari Y, Kawai H, Suemizu H, Yamazaki H. Prediction of circulating human metabolites of pemafibrate, a novel antidyslipidemic drug, using chimeric mice with humanized liver. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-7. PMID 31766940 DOI: 10.1080/00498254.2019.1694198  0.315
2019 Uehara S, Uno Y, Yamazaki H. The marmoset cytochrome P450 superfamily: sequence/phylogenetic analyses, genomic structure, and catalytic function. Biochemical Pharmacology. 113721. PMID 31751534 DOI: 10.1016/J.Bcp.2019.113721  0.353
2019 Uehara S, Yoneda N, Higuchi Y, Yamazaki H, Suemizu H. Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-8. PMID 31690163 DOI: 10.1080/00498254.2019.1688892  0.316
2019 Shimizu M, Yoda H, Nakakuki K, Saso A, Saito I, Hishinuma E, Saito S, Hiratsuka M, Yamazaki H. Genetic variants of flavin-containing monooxygenase 3 (FMO3) derived from Japanese subjects with the trimethylaminuria phenotype and whole-genome sequence data from a large Japanese database. Drug Metabolism and Pharmacokinetics. PMID 31401033 DOI: 10.1016/J.Dmpk.2019.06.001  0.323
2019 Niwa T, Narita K, Okamoto A, Murayama N, Yamazaki H. Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5. Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society For Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques. 22: 332-339. PMID 31339834 DOI: 10.18433/Jpps30558  0.349
2019 Uno Y, Murayama N, Yamazaki H. Molecular and functional characterization of cytosolic sulfotransferases in cynomolgus macaque. Biochemical Pharmacology. 166: 153-162. PMID 31100221 DOI: 10.1016/J.Bcp.2019.05.018  0.349
2019 Ikemura N, Yamaori S, Kobayashi C, Kamijo S, Murayama N, Yamazaki H, Ohmori S. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chemico-Biological Interactions. PMID 30965050 DOI: 10.1016/J.Cbi.2019.04.005  0.302
2019 Nagayoshi H, Murayama N, Kakimoto K, Tsujino M, Takenaka S, Katahira J, Lim YR, Kim D, Yamazaki H, Komori M, Guengerich FP, Shimada T. Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology. PMID 30964977 DOI: 10.1021/Acs.Chemrestox.9B00078  0.36
2019 Uno Y, Takahira R, Murayama N, Onozeki S, Kawamura S, Uehara S, Ikenaka Y, Ishizuka M, Ikushiro S, Yamazaki H. Functional and molecular characterization of UDP-glucuronosyltransferase 2 family in cynomolgus macaques. Biochemical Pharmacology. PMID 30836059 DOI: 10.1016/J.Bcp.2019.03.002  0.341
2019 Miura T, Uehara S, Mizuno S, Yoshizawa M, Murayama N, Kamiya Y, Shimizu M, Suemizu H, Yamazaki H. Steady-State Human Pharmacokinetics of Monobutyl Phthalate Predicted by Physiologically Based Pharmacokinetic Modeling Using Single-Dose Data from Humanized-Liver Mice Orally Administered with Dibutyl Phthalate. Chemical Research in Toxicology. PMID 30652481 DOI: 10.1021/Acs.Chemrestox.8B00361  0.311
2019 Takahashi T, Uno Y, Yamazaki H, Kume T. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes. Biopharmaceutics & Drug Disposition. PMID 30652318 DOI: 10.1002/Bdd.2171  0.302
2019 Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. Expression and induction ability of cytochrome P450 in human hepatocytes isolated from chimeric mice with humanized livers Drug Metabolism and Pharmacokinetics. 34. DOI: 10.1016/J.Dmpk.2018.09.160  0.329
2019 Murayama N, Guengerich FP, Yamazaki H. Cytochrome P450 3A enzyme-dependent thalidomide toxicity and inducibility in cultured human placental cells Drug Metabolism and Pharmacokinetics. 34. DOI: 10.1016/J.Dmpk.2018.09.107  0.324
2018 Uehara S, Murayama N, Yamazaki H, Suemizu H. Regioselective hydroxylation of an antiarrhythmic drug, propafenone, mediated by rat liver cytochrome P450 2D2 differs from that catalyzed by human P450 2D6. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-26. PMID 30596462 DOI: 10.1080/00498254.2018.1564401  0.365
2018 Iwata H, Goto M, Sakai N, Suemizu H, Yamazaki H. Predictability of human pharmacokinetics of diisononyl phthalate (DINP) using chimeric mice with humanized liver. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-36. PMID 30589368 DOI: 10.1080/00498254.2018.1564087  0.305
2018 Uno Y, Shimizu M, Yoda H, Origuchi Y, Yamazaki H. Non-synonymous genetic variants of flavin-containing monooxygenase 3 (FMO3) in cynomolgus macaques. Drug Metabolism and Pharmacokinetics. PMID 30420260 DOI: 10.1016/J.Dmpk.2018.09.001  0.334
2018 Uno Y, Uehara S, Murayama N, Yamazaki H. Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques. Chemical Research in Toxicology. PMID 30412386 DOI: 10.1021/Acs.Chemrestox.8B00257  0.358
2018 Uno Y, Murayama N, Yamazaki H. Molecular and Functional Characterization of N-Acetyltransferases NAT1 and NAT2 in Cynomolgus Macaque. Chemical Research in Toxicology. PMID 30358977 DOI: 10.1021/Acs.Chemrestox.8B00236  0.36
2018 Shimizu M, Yoda H, Igarashi N, Makino M, Tokuyama E, Yamazaki H. Novel variants and haplotypes of human flavin-containing monooxygenase 3 (FMO3) gene associated with Japanese subjects suffering from trimethylaminuria. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-23. PMID 30351217 DOI: 10.1080/00498254.2018.1539279  0.327
2018 Uehara S, Oshio T, Nakanishi K, Tomioka E, Suzuki M, Inoue T, Uno Y, Sasaki E, Yamazaki H. Survey of Drug Oxidation Activities in Liver and Intestine Microsomes of Individual Common Marmosets, a New Nonhuman Primate Animal Model. Current Drug Metabolism. PMID 30280664 DOI: 10.2174/1389200219666181003143312  0.35
2018 Uno Y, Murayama N, Tamura K, Yamazaki H. Functionally relevant genetic variants of glutathione S-transferase GSTM5 in cynomolgus and rhesus macaques. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-23. PMID 30216105 DOI: 10.1080/00498254.2018.1524187  0.342
2018 Uno Y, Murayama N, Kato M, Tanaka S, Ohkoshi T, Yamazaki H. Genetic variants of glutathione S-transferase GSTT1 and GSTT2 in cynomolgus macaques: identification of GSTT substrates and functionally relevant alleles. Chemical Research in Toxicology. PMID 30169019 DOI: 10.1021/Acs.Chemrestox.8B00198  0.332
2018 Makino C, Watanabe A, Deguchi T, Shiozawa H, Schreck I, Rozehnal V, Ishizuka T, Watanabe N, Ando O, Murayama N, Yamazaki H. In vivo multiple metabolic pathways for a novel G protein-coupled receptor 119 agonist DS-8500a in rats: involvement of the 1,2,4-oxadiazole ring-opening reductive reaction in livers under anaerobic conditions. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-33. PMID 30124356 DOI: 10.1080/00498254.2018.1514545  0.35
2018 Nagayoshi H, Murayama N, Kakimoto K, Takenaka S, Katahira J, Lim YR, Kim V, Kim D, Yamazaki H, Komori M, Guengerich FP, Shimada T. Site-specific oxidation of flavanone and flavone by cytochrome P450 2A6 in human liver microsomes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-51. PMID 30048196 DOI: 10.1080/00498254.2018.1505064  0.359
2018 Uehara S, Higuchi Y, Yoneda N, Yamazaki H, Suemizu H. Expression and inducibility of cytochrome P450s in human hepatocytes isolated from chimeric mice with humanized livers. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-34. PMID 29969338 DOI: 10.1080/00498254.2018.1495346  0.353
2018 Uno Y, Takahira R, Murayama N, Ishii Y, Ikenaka Y, Ishizuka M, Yamazaki H, Ikushiro S. Molecular and functional characterization of UDP-glucuronosyltransferase 1A in cynomolgus macaques. Biochemical Pharmacology. PMID 29944869 DOI: 10.1016/J.Bcp.2018.06.027  0.357
2018 Shimizu M, Suemizu H, Mizuno S, Kusama T, Miura T, Uehara S, Yamazaki H. Human plasma concentrations of trimethylamine N-oxide extrapolated using pharmacokinetic modeling based on metabolic profiles of deuterium-labeled trimethylamine in humanized-liver mice. The Journal of Toxicological Sciences. 43: 387-393. PMID 29877215 DOI: 10.2131/Jts.43.387  0.332
2018 Murayama N, Suemizu H, Uehara S, Kusama T, Mitsui M, Kamiya Y, Shimizu M, Guengerich FP, Yamazaki H. Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. The Journal of Toxicological Sciences. 43: 369-375. PMID 29877213 DOI: 10.2131/Jts.43.369  0.33
2018 Shimura K, Murayama N, Tanaka S, Onozeki S, Yamazaki H. Suitable albumin concentrations for enhanced drug oxidation activities mediated by human liver microsomal cytochrome P450 2C9 and other forms predicted with unbound fractions and partition/distribution coefficients of model substrates. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-18. PMID 29808734 DOI: 10.1080/00498254.2018.1482576  0.369
2018 Miura T, Suemizu H, Goto M, Sakai N, Iwata H, Shimizu M, Yamazaki H. Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-26. PMID 29708805 DOI: 10.1080/00498254.2018.1471753  0.322
2018 Nakanishi K, Uehara S, Kusama T, Inoue T, Shimura K, Kamiya Y, Murayama N, Shimizu M, Uno Y, Sasaki E, Yamazaki H. In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. Biochemical Pharmacology. 152: 272-278. PMID 29626440 DOI: 10.1016/J.Bcp.2018.04.002  0.401
2018 Murayama N, Yamazaki H. Cytochrome P450-dependent drug oxidation activities in commercially available hepatocytes derived from human induced pluripotent stem cells cultured for 3 weeks. The Journal of Toxicological Sciences. 43: 241-245. PMID 29618712 DOI: 10.2131/Jts.43.241  0.343
2018 Uno Y, Uehara S, Yamazaki H. Polymorphisms of cytochrome P450 2B6 (CYP2B6) in cynomolgus and rhesus macaques. Journal of Medical Primatology. PMID 29468688 DOI: 10.1111/Jmp.12336  0.354
2018 Oshio T, Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Marmoset Cytochrome P450 2B6, a Propofol Hydroxylase Expressed in Liver. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-18. PMID 29417863 DOI: 10.1080/00498254.2018.1439204  0.349
2018 Kakimoto K, Murayama N, Takenaka S, Nagayoshi H, Lim YR, Kim V, Kim D, Yamazaki H, Komori M, Guengerich FP, Shimada T. Cytochrome P450 2A6 and Other Human P450 Enzymes in the Oxidation of Flavone and Flavanone. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-49. PMID 29310511 DOI: 10.1080/00498254.2018.1426133  0.37
2018 Shimizu M, Suemizu H, Yamazaki H. Metabolic profiles of benzydamine in humanized-liver mice Drug Metabolism and Pharmacokinetics. 33. DOI: 10.1016/J.Dmpk.2017.11.269  0.303
2018 Yamazaki H, Murayama N, Shimizu M, Guengerich FP. Induction of human cytochrome P450 3A enzymes in hepatic and placental cells by thalidomide and relevance to bioactivation Drug Metabolism and Pharmacokinetics. 33. DOI: 10.1016/J.Dmpk.2017.11.114  0.345
2017 Uno Y, Uehara S, Yamazaki H. Genetic polymorphisms of drug-metabolizing cytochrome P450 enzymes in cynomolgus and rhesus monkeys and common marmosets in preclinical studies for humans. Biochemical Pharmacology. PMID 29277691 DOI: 10.1016/J.Bcp.2017.12.015  0.361
2017 Murayama N, Yajima K, Hikawa M, Shimura K, Ishii Y, Takada M, Uno Y, Utoh M, Iwasaki K, Yamazaki H. Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies. Biopharmaceutics & Drug Disposition. PMID 29136681 DOI: 10.1002/Bdd.2115  0.384
2017 Uno Y, Yamazaki H. Expression of cytochrome P450 regulators in cynomolgus macaque. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-29. PMID 28812950 DOI: 10.1080/00498254.2017.1363928  0.328
2017 Nakanishi K, Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Progesterone Hydroxylation by Cytochromes P450 2C and 3A Enzymes in Marmoset Liver Microsomes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-22. PMID 28762864 DOI: 10.1080/00498254.2017.1363444  0.363
2017 Uno Y, Osada N, Sakurai S, Shimozawa N, Iwata T, Ikeo K, Yamazaki H. Development of genotyping method for functionally relevant variants of cytochromes P450 in cynomolgus macaques. Journal of Veterinary Pharmacology and Therapeutics. PMID 28752932 DOI: 10.1111/Jvp.12443  0.344
2017 Shimizu M, Yamazaki H. Human plasma and urinary metabolic profiles of trimethylamine and trimethylamine N-oxide extrapolated using a simple physiologically based pharmacokinetic model. The Journal of Toxicological Sciences. 42: 485-490. PMID 28717107 DOI: 10.2131/Jts.42.485  0.312
2017 Toda A, Uehara S, Inoue T, Utoh M, Kusama T, Shimizu M, Uno Y, Mogi M, Sasaki E, Yamazaki H. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol, and midazolam in common marmosets genotyped for cytochrome P450 2C19. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-21. PMID 28686070 DOI: 10.1080/00498254.2017.1353716  0.347
2017 Uehara S, Uno Y, Yamazaki H. Hepatic expression of cytochrome P450 enzymes in non-human primate species. Journal of Medical Primatology. PMID 28664555 DOI: 10.1111/Jmp.12288  0.358
2017 Shimada T, Murayama N, Kakimoto K, Takenaka S, Lim YR, Yeom S, Kim D, Yamazaki H, Guengerich FP, Komori M. Oxidation of 1-Chloropyrene by Human CYP1 Family and CYP2A Subfamily Cytochrome P450 Enzymes: Catalytic Roles of Two CYP1B1 and Five CYP2A13 Allelic Variants. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-42. PMID 28648140 DOI: 10.1080/00498254.2017.1347306  0.363
2017 Utoh M, Miura T, Kusama T, Uehara S, Shimizu M, Uno Y, Yamazaki H. Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Biopharmaceutics & Drug Disposition. PMID 28608515 DOI: 10.1002/Bdd.2084  0.354
2017 Murayama N, Kazuki Y, Satoh D, Arata K, Harada T, Shibata N, Guengerich FP, Yamazaki H. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. The Journal of Toxicological Sciences. 42: 343-348. PMID 28496040 DOI: 10.2131/Jts.42.343  0.365
2017 Uehahara S, Ishii S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Regio- and stereo-selective oxidation of a cardiovascular drug metoprolol mediated by cytochrome P450 2D and 3A enzymes in marmoset livers. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28495902 DOI: 10.1124/Dmd.117.075630  0.378
2017 Uehara S, Uno Y, Okamoto E, Inoue T, Sasaki E, Yamazaki H. Molecular cloning and characterization of marmoset aldehyde oxidase. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28487309 DOI: 10.1124/Dmd.117.076042  0.378
2017 Uehara S, Uno Y, Tomioka E, Inoue T, Sasaki E, Yamazaki H. Functional characterization and tissue expression of marmoset cytochrome P450 2E1. Biopharmaceutics & Drug Disposition. PMID 28474789 DOI: 10.1002/Bdd.2080  0.331
2017 Uehara S, Yuki Y, Uno Y, Inoue T, Sasaki E, Yamazaki H. Terfenadine t-butyl hydroxylation catalyzed by human and marmoset cytochrome P450 3A and 4F enzymes in livers and small intestines. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-20. PMID 28436281 DOI: 10.1080/00498254.2017.1321811  0.368
2017 Uehara S, Shimizu M, Uno Y, Inoue T, Sasaki E, Yamazaki H. Marmoset flavin-containing monooxygenase 3 in liver is a major benzydamine and sulindac sulfide oxygenase. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28258069 DOI: 10.1124/Dmd.117.075184  0.371
2017 Uehara S, Uno Y, Nakanishi K, Ishii S, Inoue T, Sasaki E, Yamazaki H. Marmoset cytochrome P450 3A4 expressed in liver and small intestine tissues efficiently metabolizes midazolam, alprazolam, nifedipine, and testosterone. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28196829 DOI: 10.1124/Dmd.116.074898  0.354
2017 Yamazaki-Nishioka M, Shimizu M, Suemizu H, Nishiwaki M, Mitsui M, Yamazaki H. Human Plasma Metabolic Profiles of Benzydamine, a Flavin-containing Monooxygenase Probe Substrate, Simulated with Pharmacokinetic Data from Control and Humanized-liver Mice. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-26. PMID 28145791 DOI: 10.1080/00498254.2017.1288280  0.321
2017 Utoh M, Kusama T, Miura T, Mitsui M, Kawano M, Hirano T, Shimizu M, Uno Y, Yamazaki H. R-Warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-18. PMID 28136132 DOI: 10.1080/00498254.2017.1288945  0.323
2017 Ito S, Chijiwa H, Okuzono T, Ishiguro T, Yamamoto Y, Nishinoaki S, Kuronuma M, Suemizu H, Kalgutkar AS, Kamimura H, Ninomiya S, Yamazaki H. Elucidation of parmacokinetics of PF-04937319, a partial glucokinase activator, and its disproportionate n-demethylated metabolite in chimeric mice with humanized livers Drug Metabolism and Pharmacokinetics. 32. DOI: 10.1016/J.Dmpk.2016.10.300  0.31
2017 Niwa T, Murayama N, Imagawa Y, Yamazaki H. Comparison of catalytic and inhibitory properties in human drug-metabolizing cytochrome P450 3A4 and 3A5 for various compounds including endogenous steroid hormones and azole antifungals by molecular docking simulation Drug Metabolism and Pharmacokinetics. 32. DOI: 10.1016/J.Dmpk.2016.10.164  0.329
2017 Yamazaki H. Human and monkey P450 metabolism for human-specific metabolite formation Drug Metabolism and Pharmacokinetics. 32. DOI: 10.1016/J.Dmpk.2016.10.090  0.329
2016 Uno Y, Takata R, Kito G, Yamazaki H, Nakagawa K, Nakamura Y, Kamataki T, Katagiri T. Sex- and age-dependent gene expression in human liver: An implication for drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics. PMID 28153492 DOI: 10.1016/J.Dmpk.2016.10.409  0.308
2016 Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Cloning and expression of a novel catechol-O-methyltransferase in common marmosets. The Journal of Veterinary Medical Science. PMID 27890888 DOI: 10.1292/Jvms.16-0459  0.315
2016 Murayama N, Shimizu M, KObayashi K, KIshimoto I, Yamazaki H. Cytochrome P450 2A6 Phenotyping Using Dietary Caffeine Salivary Metabolite Ratios and Genotyping Using Blood on Storage Cards in Non-smoking Japanese Volunteers. Drug Metabolism Letters. PMID 27842485 DOI: 10.2174/1872312810666161114144008  0.312
2016 Uehara S, Uno Y, Suzuki T, Inoue T, Utoh M, Sasaki E, Yamazaki H. Strong induction of cytochrome P450 1A/3A, but not P450 2B, in cultured hepatocytes from common marmosets and cynomolgus monkeys by typical human P450 inducing agents. Drug Metabolism Letters. PMID 27842484 DOI: 10.2174/1872312810666161114144412  0.346
2016 Yamazaki H. Differences in Toxicological and Pharmacological Responses Mediated by Polymorphic Cytochromes P450 and Related Drug-metabolizing Enzymes. Chemical Research in Toxicology. PMID 27750412 DOI: 10.1021/Acs.Chemrestox.6B00286  0.363
2016 Uehara S, Kawano M, Murayama N, Uno Y, Utoh M, Inoue T, Sasaki E, Yamazaki H. Oxidation of R- and S-omeprazole stereoselectively mediated by liver microsomal cytochrome P450 2C19 enzymes from cynomolgus monkeys and common marmosets. Biochemical Pharmacology. PMID 27641812 DOI: 10.1016/J.Bcp.2016.09.010  0.374
2016 Shimada T, Kakimoto K, Takenaka S, Koga N, Uehara S, Murayama N, Yamazaki H, Kim D, Guengerich FP, Komori M. Roles of Human CYP2A6 and Monkey CYP2A24 and 2A26 Cytochrome P450 Enzymes in the Oxidation of 2,5,2',5'-Tetrachlorobiphenyl. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27625140 DOI: 10.1124/Dmd.116.072991  0.375
2016 Yamazaki H, Suemizu H, Kazuki Y, Oofusa K, Kuribayashi S, Shimizu M, Ninomiya S, Horie T, Shibata N, Guengerich FP. Assessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-chromosome or Hepatocytes by Two-dimensional Electrophoresis/Accelerator Mass Spectrometry. Chemical Research in Toxicology. PMID 27464947 DOI: 10.1021/Acs.Chemrestox.6B00210  0.353
2016 Uehara S, Uno Y, Ishii S, Inoue T, Sasaki E, Yamazaki H. Marmoset cytochrome P450 4A11, a novel arachidonic acid and lauric acid ω-hydroxylase expressed in liver and kidney tissues. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-9. PMID 27435360 DOI: 10.1080/00498254.2016.1206673  0.348
2016 Iwasaki K, Kitsugi Y, Ikeda K, Yoshikawa T, Hosaka S, Uehara S, Uno Y, Utoh M, Yamazaki H. In vivo individual variations in pharmacokinetics of efavirenz in cynomolgus monkeys genotyped for cytochrome P450 2C9. Biopharmaceutics & Drug Disposition. PMID 27417918 DOI: 10.1002/Bdd.2021  0.339
2016 Kamimura H, Ito S, Chijiwa H, Okuzono T, Ishiguro T, Yamamoto Y, Nishinoaki S, Ninomiya SI, Mitsui M, Kalgutkar AS, Yamazaki H, Suemizu H. Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-12. PMID 27389028 DOI: 10.1080/00498254.2016.1199063  0.342
2016 Yamazaki H, Suemizu H, Mitsui M, Shimizu M, Guengerich FP. Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, And Physiologically-Based Pharmacokinetic Modeling in Toxicology. Chemical Research in Toxicology. PMID 27337115 DOI: 10.1021/Acs.Chemrestox.6B00136  0.36
2016 Uno Y, Uehara S, Yamazaki H. Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochemical Pharmacology. PMID 27318253 DOI: 10.1016/J.Bcp.2016.06.008  0.375
2016 Sakai C, Iwano S, Shimizu M, Onodera J, Uchida M, Sakurada E, Yamazaki Y, Asaoka Y, Imura N, Uno Y, Murayama N, Hayashi R, Yamazaki H, Miyamoto Y. Analysis of gene expression for microminipig liver transcriptomes using parallel long-read technology and short-read sequencing. Biopharmaceutics & Drug Disposition. 37: 220-232. PMID 27214158 DOI: 10.1002/Bdd.2007  0.329
2016 Shimada T, Takenaka S, Kakimoto K, Murayama N, Lim YR, Kim D, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. Structure-Function Studies of Naphthalene, Phenanthrene, Biphenyl, and their Alkynyl Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology. PMID 27137136 DOI: 10.1021/Acs.Chemrestox.6B00083  0.311
2016 Uehara S, Uno Y, Inoue T, Kawano M, Shimizu M, Toda A, Utoh M, Sasaki E, Yamazaki H. Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27098744 DOI: 10.1124/Dmd.116.070383  0.369
2016 Uehara S, Uno Y, Yuki Y, Inoue T, Sasaki E, Yamazaki H. A new marmoset P450 4F12 enzyme expressed in small intestines and livers efficiently metabolizes an anti-histaminic drug ebastine. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27044800 DOI: 10.1124/Dmd.116.070367  0.309
2016 Utoh M, Suemizu H, Mitsui M, Kawano M, Toda A, Uehara S, Uno Y, Shimizu M, Sasaki E, Yamazaki H. Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-7. PMID 26916082 DOI: 10.3109/00498254.2016.1147102  0.334
2016 Kazuki Y, Akita M, Kobayashi K, Osaki M, Satoh D, Ohta R, Abe S, Takehara S, Kazuki K, Yamazaki H, Kamataki T, Oshimura M. Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model. Scientific Reports. 6: 21419. PMID 26903378 DOI: 10.1038/Srep21419  0.335
2016 Uehara S, Uno Y, Inoue T, Okamoto E, Sasaki E, Yamazaki H. Marmoset cytochrome P450 2J2 mainly expressed in small intestines and livers effectively metabolizes human P450 2J2 probe substrates, astemizole and terfenadine. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-9. PMID 26899760 DOI: 10.3109/00498254.2016.1146366  0.37
2016 Shida S, Yamazaki H. Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica. 46: 759-764. PMID 26652678 DOI: 10.3109/00498254.2015.1118650  0.317
2016 Uno Y, Yamazaki H. Development of a genotyping tool for a functionally relevant CYP2C19 allele (Phe100Asn, Ala103Val and Ile112Leu) in cynomolgus macaques. Journal of Veterinary Medical Science. 78: 147-148. PMID 26300440 DOI: 10.1292/Jvms.15-0416  0.332
2016 Okubo M, Morita S, Murayama N, Akimoto Y, Goto A, Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of antipsychotic risperidone from Japanese subjects genotyped for cytochrome P450 2D6 and 3A5 Human Psychopharmacology. DOI: 10.1002/Hup.2516  0.357
2016 Okubo M, Narita M, Murayama N, Akimoto Y, Goto A, Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3 Human Psychopharmacology. DOI: 10.1002/Hup.2515  0.342
2015 Hosaka S, Murayama N, Satsukawa M, Uehara S, Shimizu M, Iwasaki K, Iwano S, Uno Y, Yamazaki H. Identification of putative substrates for cynomolgus monkey cytochrome P450 2C8 by substrate depletion assays with 22 human P450 substrates and inhibitors. Biopharmaceutics & Drug Disposition. PMID 26581561 DOI: 10.1002/Bdd.1998  0.36
2015 Uehara S, Uno Y, Inoue T, Suzuki T, Utoh M, Sasaki E, Yamazaki H. Caffeine 7-N-demethylation and C-8-oxidation mediated by liver microsomal cytochrome P450 enzymes in common marmosets. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-6. PMID 26503341 DOI: 10.3109/00498254.2015.1096980  0.379
2015 Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Molecular cloning, tissue distribution, and functional characterization of marmoset cytochrome P450 1A1, 1A2, and 1B1. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 26502772 DOI: 10.1124/Dmd.115.067561  0.341
2015 Nishiyama S, Suemizu H, Shibata N, Guengerich FP, Yamazaki H. Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice. Chemical Research in Toxicology. PMID 26492539 DOI: 10.1021/Acs.Chemrestox.5B00381  0.316
2015 Hosaka S, Murayama N, Satsukawa M, Uehara S, Shimizu M, Iwasaki K, Iwano S, Uno Y, Yamazaki H. Similar substrate specificity of cynomolgus monkey cytochrome P450 2C19 to reported human P450 2C counterpart enzymes by evaluation of 89 drug clearances. Biopharmaceutics & Drug Disposition. PMID 26348733 DOI: 10.1002/Bdd.1991  0.361
2015 Shimada T, Takenaka S, Murayama N, Kramlinger VM, Kim JH, Kim D, Liu J, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. Oxidation of pyrene, 1-hydroxypyrene, 1-nitropyrene and 1-acetylpyrene by human cytochrome P450 2A13. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-14. PMID 26247835 DOI: 10.3109/00498254.2015.1069419  0.343
2015 Uehara S, Uno Y, Inoue T, Kawano M, Shimizu M, Toda A, Utoh M, Sasaki E, Yamazaki H. Novel Marmoset Cytochrome P450 2C19 in Livers Efficiently Metabolizes Human P450 2C9 and 2C19 Substrates, S-Warfarin, Tolbutamide, Flurbiprofen, and Omeprazole. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1408-16. PMID 26228688 DOI: 10.1124/Dmd.115.066100  0.346
2015 Uno T, Ogura C, Izumi C, Nakamura M, Yanase T, Yamazaki H, Ashida H, Kanamaru K, Yamagata H, Imaishi H. Point mutation of cytochrome P450 2A6 (a polymorphic variant CYP2A6.25) confers new substrate specificity towards flavonoids. Biopharmaceutics & Drug Disposition. PMID 26222491 DOI: 10.1002/Bdd.1966  0.35
2015 Uehara S, Inoue T, Utoh M, Toda A, Shimizu M, Uno Y, Sasaki E, Yamazaki H. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-6. PMID 26114209 DOI: 10.3109/00498254.2015.1057270  0.376
2015 Shida S, Utoh M, Murayama N, Shimizu M, Uno Y, Yamazaki H. Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 45: 881-6. PMID 26075833 DOI: 10.3109/00498254.2015.1028511  0.317
2015 Hosaka S, Murayama N, Satsukawa M, Uehara S, Shimizu M, Iwasaki K, Iwano S, Uno Y, Yamazaki H. Comprehensive Evaluation for Substrate Selectivity of Cynomolgus Monkey Cytochrome P450 2C9, a New Efavirenz Oxidase. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1119-22. PMID 25948712 DOI: 10.1124/Dmd.115.063925  0.365
2015 Adachi K, Suemizu H, Murayama N, Shimizu M, Yamazaki H. Human biofluid concentrations of mono(2-ethylhexyl)phthalate extrapolated from pharmacokinetics in chimeric mice with humanized liver administered with di(2-ethylhexyl)phthalate and physiologically based pharmacokinetic modeling. Environmental Toxicology and Pharmacology. 39: 1067-73. PMID 25867688 DOI: 10.1016/J.Etap.2015.02.011  0.301
2015 Uehara S, Uno Y, Inoue T, Sasaki E, Yamazaki H. Substrate Selectivities and Catalytic Activities of Marmoset Liver Cytochrome P450 2A6 Differed from Those of Human P450 2A6. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 969-76. PMID 25858611 DOI: 10.1124/Dmd.115.063909  0.324
2015 Miyaguchi T, Suemizu H, Shimizu M, Shida S, Nishiyama S, Takano R, Murayama N, Yamazaki H. Human urine and plasma concentrations of bisphenol A extrapolated from pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and semi-physiological pharmacokinetic modeling. Regulatory Toxicology and Pharmacology : Rtp. 72: 71-6. PMID 25805149 DOI: 10.1016/J.Yrtph.2015.03.010  0.309
2015 Uehara S, Uno Y, Hagihira Y, Murayama N, Shimizu M, Inoue T, Sasaki E, Yamazaki H. Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-7. PMID 25801057 DOI: 10.3109/00498254.2015.1019595  0.32
2015 Utoh M, Yoshikawa T, Hayashi Y, Shimizu M, Iwasaki K, Uno Y, Yamazaki H. Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochemical Pharmacology. 95: 110-4. PMID 25801008 DOI: 10.1016/J.Bcp.2015.03.008  0.343
2015 Uno Y, Matsushita A, Murayama N, Yamazaki H. Genetic polymorphism of cynomolgus and rhesus macaque CYP2C9. Drug Metabolism and Pharmacokinetics. 30: 130-2. PMID 25760542 DOI: 10.1016/J.Dmpk.2014.10.002  0.336
2015 Taniguchi-Takizawa T, Shimizu M, Kume T, Yamazaki H. Benzydamine N-oxygenation as an index for flavin-containing monooxygenase activity and benzydamine N-demethylation by cytochrome P450 enzymes in liver microsomes from rats, dogs, monkeys, and humans Drug Metabolism and Pharmacokinetics. 30: 64-69. PMID 25760531 DOI: 10.1016/J.Dmpk.2014.09.006  0.328
2015 Uehara S, Uno Y, Inoue T, Murayama N, Shimizu M, Sasaki E, Yamazaki H. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 735-42. PMID 25735838 DOI: 10.1124/Dmd.115.063594  0.366
2015 Uno Y, Uehara S, Kohara S, Osada N, Murayama N, Yamazaki H. CYP2D44 polymorphisms in cynomolgus and rhesus macaques. Molecular Biology Reports. 42: 1149-55. PMID 25682269 DOI: 10.1007/S11033-015-3863-0  0.327
2015 Niwa T, Murayama N, Imagawa Y, Yamazaki H. Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metabolism Reviews. 47: 89-110. PMID 25678418 DOI: 10.3109/03602532.2015.1011658  0.361
2015 Shimada T, Takenaka S, Murayama N, Yamazaki H, Kim JH, Kim D, Yoshimoto FK, Guengerich FP, Komori M. Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. Chemical Research in Toxicology. PMID 25642975 DOI: 10.1021/Tx500505Y  0.321
2015 Murayama N, Usui T, Slawny N, Chesne C, Yamazaki H. Human HepaRG Cells can be Cultured in Hanging-drop Plates for Cytochrome P450 Induction and Function Assays. Drug Metabolism Letters. 9: 3-7. PMID 25600204 DOI: 10.2174/1872312809666150119104806  0.316
2015 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H. Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients. Biochemical Pharmacology. 93: 104-9. PMID 25475885 DOI: 10.1016/J.Bcp.2014.11.011  0.374
2015 Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Current Drug Metabolism. 15: 651-679. PMID 25429674 DOI: 10.2174/1389200215666141125121511  0.356
2015 Koyanagi T, Nakanishi Y, Murayama N, Yamaura Y, Ikeda K, Yano K, Uehara S, Utoh M, Kim S, Uno Y, Yamazaki H. Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 45: 312-21. PMID 25364857 DOI: 10.3109/00498254.2014.979271  0.316
2015 Hosaka S, Murayama N, Satsukawa M, Shimizu M, Uehara S, Fujino H, Iwasaki K, Iwano S, Uno Y, Yamazaki H. Evaluation of 89 compounds for identification of substrates for cynomolgus monkey CYP2C76, a new bupropion/nifedipine oxidase. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 27-33. PMID 25318994 DOI: 10.1124/Dmd.114.061275  0.365
2015 Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H, Uno Y. Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 45: 124-30. PMID 25138712 DOI: 10.3109/00498254.2014.952800  0.342
2015 Shimizu M, Origuchi Y, Ikuma M, Mitsuhashi N, Yamazaki H. Analysis of six novel flavin-containing monooxygenase 3 (FMO3) gene variants found in a Japanese population suffering from trimethylaminuria Molecular Genetics and Metabolism Reports. 5: 89-93. DOI: 10.1016/J.Ymgmr.2015.10.013  0.312
2015 Shimizu M, Shiraishi A, Sato A, Nagashima S, Yamazaki H. Potential for drug interactions mediated by polymorphic flavin-containing monooxygenase 3 in human livers Drug Metabolism and Pharmacokinetics. 30: 70-74. DOI: 10.1016/J.Dmpk.2014.09.008  0.304
2015 Shimizu M, Koyama T, Kishimoto I, Yamazaki H. Dataset for genotyping validation of cytochrome P450 2A6 whole-gene deletion (CYP2A6*4) by real-time polymerase chain reaction platforms Data in Brief. 5: 642-645. DOI: 10.1016/J.Dib.2015.10.019  0.321
2014 Uno Y, Hosaka S, Yamazaki H. Identification and analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in cynomolgus macaques. Journal of Veterinary Medical Science. 76: 1647-1650. PMID 25649950 DOI: 10.1292/Jvms.14-0313  0.359
2014 Uno Y, Matsushita A, Shukuya M, Matsumoto Y, Murayama N, Yamazaki H. CYP2C19 polymorphisms account for inter-individual variability of drug metabolism in cynomolgus macaques. Biochemical Pharmacology. 91: 242-8. PMID 25036290 DOI: 10.1016/J.Bcp.2014.07.004  0.364
2014 Yamashita M, Suemizu H, Murayama N, Nishiyama S, Shimizu M, Yamazaki H. Human plasma concentrations of herbicidal carbamate molinate extrapolated from the pharmacokinetics established in in vivo experiments with chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology : Rtp. 70: 214-21. PMID 25016177 DOI: 10.1016/J.Yrtph.2014.06.028  0.321
2014 Uno Y, Uehara S, Kohara S, Murayama N, Yamazaki H. Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: an evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1407-10. PMID 24985704 DOI: 10.1124/Dmd.114.059220  0.35
2014 Shimizu M, Iwano S, Uno Y, Uehara S, Inoue T, Murayama N, Onodera J, Sasaki E, Yamazaki H. Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. Plos One. 9: e100936. PMID 24977701 DOI: 10.1371/Journal.Pone.0100936  0.348
2014 Yamazaki M, Shimizu M, Uno Y, Yamazaki H. Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochemical Pharmacology. 90: 159-65. PMID 24821112 DOI: 10.1016/J.Bcp.2014.04.019  0.326
2014 Higashi E, Ando A, Iwano S, Murayama N, Yamazaki H, Miyamoto Y. Hepatic microsomal UDP-glucuronosyltransferase (UGT) activities in the microminipig. Biopharmaceutics & Drug Disposition. 35: 313-20. PMID 24752421 DOI: 10.1002/Bdd.1898  0.358
2014 Nakamaru Y, Hayashi Y, Sekine M, Kinoshita S, Thompson J, Kawaguchi A, Davies M, Jürgen Heuer H, Yamazaki H, Akimoto K. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany. Clinical Therapeutics. 36: 760-9. PMID 24726088 DOI: 10.1016/J.Clinthera.2014.03.002  0.306
2014 Uehara S, Murayama N, Nakanishi Y, Nakamura C, Hashizume T, Zeldin DC, Yamazaki H, Uno Y. Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 44: 769-74. PMID 24593267 DOI: 10.3109/00498254.2014.895882  0.35
2014 Yajima K, Uno Y, Murayama N, Uehara S, Shimizu M, Nakamura C, Iwasaki K, Utoh M, Yamazaki H. Evaluation of 23 lots of commercially available cryopreserved hepatocytes for induction assays of human cytochromes P450. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 867-71. PMID 24553381 DOI: 10.1124/Dmd.113.056804  0.341
2014 Niwa T, Yasumura M, Murayama N, Yamazaki H. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation. Drug Metabolism Letters. 8: 43-50. PMID 24484539 DOI: 10.2174/1872312807666131229121228  0.357
2014 Murayama N, van Beuningen R, Suemizu H, Guguen-Guillouzo C, Shibata N, Yajima K, Utoh M, Shimizu M, Chesné C, Nakamura M, Guengerich FP, Houtman R, Yamazaki H. Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor. Chemical Research in Toxicology. 27: 304-8. PMID 24460184 DOI: 10.1021/Tx4004374  0.348
2014 Chowdhury G, Shibata N, Yamazaki H, Guengerich FP. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chemical Research in Toxicology. 27: 147-56. PMID 24350712 DOI: 10.1021/Tx4004215  0.345
2014 Higuchi Y, Kawai K, Yamazaki H, Nakamura M, Bree F, Guguen-Guillouzo C, Suemizu H. The human hepatic cell line HepaRG as a possible cell source for the generation of humanized liver TK-NOG mice. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 44: 146-53. PMID 24066694 DOI: 10.3109/00498254.2013.836257  0.312
2014 Ohyama K, Murayama N, Shimizu M, Yamazaki H. Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 44: 10-6. PMID 23777257 DOI: 10.3109/00498254.2013.806837  0.377
2013 Uno Y, Murayama N, Kunori M, Yamazaki H. Systematic identification and characterization of glutathione S-transferases in cynomolgus macaque. Biochemical Pharmacology. 86: 679-90. PMID 23827461 DOI: 10.1016/J.Bcp.2013.06.022  0.347
2013 Uno Y, Murayama N, Kunori M, Yamazaki H. Characterization of microsomal glutathione S-transferases MGST1, MGST2, and MGST3 in cynomolgus macaque. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1621-5. PMID 23785063 DOI: 10.1124/Dmd.113.052977  0.361
2013 Utoh M, Murayama N, Uno Y, Onose Y, Hosaka S, Fujino H, Shimizu M, Iwasaki K, Yamazaki H. Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 43: 1037-42. PMID 23679834 DOI: 10.3109/00498254.2013.793874  0.379
2013 Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. The Journal of Toxicological Sciences. 38: 349-54. PMID 23665933 DOI: 10.2131/Jts.38.349  0.345
2013 Nakanishi Y, Yamashita H, Yoshikawa T, Tominaga T, Nojiri K, Sunaga Y, Muneoka A, Iwasaki K, Utoh M, Nakamura C, Yamazaki H, Uno Y. Cytochrome P450 Metabolic Activities in the Small Intestine of Cynomolgus Macaques Bred in Cambodia, China, and Indonesia Drug Metabolism and Pharmacokinetics. 28: 510-513. PMID 23648676 DOI: 10.2133/Dmpk.Dmpk-13-Nt-031  0.352
2013 Uno Y, Shimizu M, Yamazaki H. Molecular and functional characterization of flavin-containing monooxygenases in cynomolgus macaque. Biochemical Pharmacology. 85: 1837-1847. PMID 23623750 DOI: 10.1016/J.Bcp.2013.04.012  0.349
2013 Yamazaki H, Shimizu M. Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities Biochemical Pharmacology. 85: 1588-1593. PMID 23567996 DOI: 10.1016/J.Bcp.2013.03.020  0.331
2013 Shimada T, Murayama N, Yamazaki H, Tanaka K, Takenaka S, Komori M, Kim D, Guengerich FP. Metabolic activation of polycyclic aromatic hydrocarbons and aryl and heterocyclic amines by human cytochromes P450 2A13 and 2A6. Chemical Research in Toxicology. 26: 529-37. PMID 23432465 DOI: 10.1021/Tx3004906  0.35
2013 Shimada T, Kim D, Murayama N, Tanaka K, Takenaka S, Nagy LD, Folkman LM, Foroozesh MK, Komori M, Yamazaki H, Guengerich FP. Binding of diverse environmental chemicals with human cytochromes P450 2A13, 2A6, and 1B1 and enzyme inhibition. Chemical Research in Toxicology. 26: 517-28. PMID 23432429 DOI: 10.1021/Tx300492J  0.326
2013 Yamazaki H, Suemizu H, Murayama N, Utoh M, Shibata N, Nakamura M, Guengerich FP. In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice. Chemical Research in Toxicology. 26: 486-9. PMID 23419139 DOI: 10.1021/Tx400008G  0.361
2013 Tsukada A, Suemizu H, Murayama N, Takano R, Shimizu M, Nakamura M, Yamazaki H. Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling. Regulatory Toxicology and Pharmacology : Rtp. 65: 316-24. PMID 23395687 DOI: 10.1016/J.Yrtph.2013.01.008  0.325
2013 Ueng YF, Chen CC, Yamazaki H, Kiyotani K, Chang YP, Lo WS, Li DT, Tsai PL. Mechanism-based inhibition of CYP1A1 and CYP3A4 by the furanocoumarin chalepensin. Drug Metabolism and Pharmacokinetics. 28: 229-38. PMID 23257392 DOI: 10.2133/Dmpk.Dmpk-12-Rg-113  0.344
2013 Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, Yamazaki H. Comparison of P450 Enzymes Between Cynomolgus Monkeys and Humans: P450 Identities, Protein Contents, Kinetic Parameters, and Potential for Inhibitory Profiles Current Drug Metabolism. 14: 239-252. DOI: 10.2174/1389200211314020012  0.384
2012 Mogi M, Toda A, Iwasaki K, Kusumoto S, Takehara H, Shimizu M, Murayama N, Izumi H, Utoh M, Yamazaki H. Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. The Journal of Toxicological Sciences. 37: 1157-64. PMID 23208431 DOI: 10.2131/Jts.37.1157  0.371
2012 Hosoi Y, Uno Y, Murayama N, Fujino H, Shukuya M, Iwasaki K, Shimizu M, Utoh M, Yamazaki H. Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation. Biochemical Pharmacology. 84: 1691-5. PMID 23041648 DOI: 10.1016/J.Bcp.2012.09.026  0.361
2012 Shimizu M, Kobayashi Y, Hayashi S, Aoki Y, Yamazaki H. Variants in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Molecular Genetics and Metabolism. 107: 330-334. PMID 22819296 DOI: 10.1016/J.Ymgme.2012.06.014  0.327
2012 Niwa T, Yamazaki H. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition. Current Drug Metabolism. 13: 1145-1159. PMID 22571484 DOI: 10.2174/138920012802850092  0.321
2012 Yamazaki H, Suemizu H, Shimizu M, Igaya S, Shibata N, Nakamura M, Chowdhury G, Guengerich FP. In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice. Chemical Research in Toxicology. 25: 274-6. PMID 22268628 DOI: 10.1021/Tx300009J  0.312
2012 Ise R, Nakanishi Y, Kohara S, Yamashita H, Yoshikawa T, Iwasaki K, Nagata R, Fukuzaki K, Utoh M, Nakamura C, Yamazaki H, Uno Y. Expression profile of hepatic genes in cynomolgus macaques bred in Cambodia, China, and Indonesia: implications for cytochrome P450 genes. Drug Metabolism and Pharmacokinetics. 27: 307-316. PMID 22166892 DOI: 10.2133/Dmpk.Dmpk-11-Rg-133  0.32
2012 Uehara S, Murayama N, Yamazaki H, Uno Y. CYP2C76 non-synonymous variants in cynomolgus and rhesus macaques. Drug Metabolism and Pharmacokinetics. 27: 344-8. PMID 22123125 DOI: 10.2133/Dmpk.Dmpk-11-Nt-118  0.325
2012 Kuribayashi S, Uno Y, Naito S, Yamazaki H. Different metabolites of human hepatotoxic pyrazolopyrimidine derivative 5-n-butyl-pyrazolo[1,5-a]pyrimidine produced by human, rat and monkey cytochrome P450 1A2 and liver microsomes. Basic & Clinical Pharmacology & Toxicology. 110: 405-408. PMID 22017768 DOI: 10.1111/J.1742-7843.2011.00823.X  0.364
2011 Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, Uno Y. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. The Journal of Pharmacology and Experimental Therapeutics. 339: 654-61. PMID 21849623 DOI: 10.1124/Jpet.111.185009  0.39
2011 Ise R, Kondo S, Kato H, Imai N, Akiyama H, Iwasaki K, Yamazaki H, Uno Y. Expression of cytochromes p450 in fetal, infant, and juvenile liver of cynomolgus macaques. Drug Metabolism and Pharmacokinetics. 26: 621-626. PMID 21844657 DOI: 10.2133/Dmpk.Dmpk-11-Nt-057  0.311
2011 Shimada T, Murayama N, Tanaka K, Takenaka S, Guengerich FP, Yamazaki H, Komori M. Spectral modification and catalytic inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2A6, and 2A13 by four chemopreventive organoselenium compounds. Chemical Research in Toxicology. 24: 1327-37. PMID 21732699 DOI: 10.1021/Tx200218U  0.317
2011 Niwa T, Murayama N, Umeyama H, Shimizu M, Yamazaki H. Human liver enzymes responsible for metabolic elimination of tyramine; a vasopressor agent from daily food. Drug Metabolism Letters. 5: 216-9. PMID 21679153 DOI: 10.2174/187231211796905026  0.367
2011 Uno Y, Matsuno K, Murayama N, Nakamura C, Yamazaki H. Metabolism of P450 probe substrates by cynomolgus monkey CYP2C76. Basic & Clinical Pharmacology & Toxicology. 109: 315-8. PMID 21651728 DOI: 10.1111/J.1742-7843.2011.00740.X  0.308
2011 Shibahara N, Masunaga Y, Iwano S, Yamazaki H, Kiyotani K, Kamataki T. Human cytochrome P450 1A1 is a novel target gene of liver X receptor α. Drug Metabolism and Pharmacokinetics. 26: 451-457. PMID 21646728 DOI: 10.2133/Dmpk.Dmpk-11-Rg-030  0.355
2011 Niwa T, Murayama N, Yamazaki H. Stereoselectivity of human cytochrome p450 in metabolic and inhibitory activities. Current Drug Metabolism. 12: 549-69. PMID 21476971 DOI: 10.2174/138920011795713724  0.353
2011 Niwa T, Murayama N, Yamazaki H. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. Current Drug Metabolism. 12: 412-35. PMID 21453270 DOI: 10.2174/138920011795495286  0.357
2011 Ueng YF, Chen CC, Chung YT, Liu TY, Chang YP, Lo WS, Murayama N, Yamazaki H, Souček P, Chau GY, Chi CW, Chen RM, Li DT. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. British Journal of Pharmacology. 163: 1250-62. PMID 21418183 DOI: 10.1111/J.1476-5381.2011.01341.X  0.358
2011 Uno Y, Uehara S, Kohara S, Iwasaki K, Nagata R, Fukuzaki K, Utoh M, Murayama N, Yamazaki H. Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey. Plos One. 6: e16923. PMID 21347438 DOI: 10.1371/Journal.Pone.0016923  0.352
2011 Uno Y, Iwasaki K, Yamazaki H, Nelson DR. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metabolism Reviews. 43: 346-61. PMID 21303270 DOI: 10.3109/03602532.2010.549492  0.338
2011 Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 757-62. PMID 21266595 DOI: 10.1124/Dmd.110.037853  0.365
2011 Uno Y, Uehara S, Murayama N, Yamazaki H. CYP2G2, pseudogenized in human, is expressed in nasal mucosa of cynomolgus monkey and encodes a functional drug-metabolizing enzyme. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 717-23. PMID 21189332 DOI: 10.1124/Dmd.110.036574  0.323
2011 Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Cynomolgus macaque CYP4 isoforms are functional, metabolizing arachidonic acid. Journal of Veterinary Medical Science. 73: 487-490. PMID 21099187 DOI: 10.1292/Jvms.10-0333  0.316
2011 Uno Y, Uehara S, Murayama N, Yamazaki H. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey Biochemical Pharmacology. 81: 442-450. PMID 21070747 DOI: 10.1016/J.Bcp.2010.11.003  0.35
2011 Emoto C, Iwasaki K, Murayama N, Yamazaki H. Drug Metabolism and Toxicity in Chimeric Mice with Humanized Liver Journal of Health Science. 57: 22-27. DOI: 10.1248/Jhs.57.22  0.376
2011 Emoto C, Iwasaki K, Koizumi R, Utoh M, Murayama N, Uno Y, Yamazaki H. Species difference between cynomolgus monkeys and humans on cytochromes P450 2D and 3A-dependent drug oxidation activities in liver microsomes Journal of Health Science. 57: 164-170. DOI: 10.1248/Jhs.57.164  0.393
2010 Shimada T, Tanaka K, Takenaka S, Murayama N, Martin MV, Foroozesh MK, Yamazaki H, Guengerich FP, Komori M. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chemical Research in Toxicology. 23: 1921-35. PMID 21053930 DOI: 10.1021/Tx100286D  0.325
2010 Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution Current Drug Metabolism. 11: 678-685. PMID 20973757 DOI: 10.2174/138920010794233503  0.331
2010 Uehara S, Murayama N, Yamazaki H, Uno Y. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin Xenobiotica. 40: 621-629. PMID 20929430 DOI: 10.3109/00498254.2010.501118  0.364
2010 Iwasaki K, Murayama N, Koizumi R, Uno Y, Yamazaki H. Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans Drug Metabolism and Pharmacokinetics. 25: 388-391. PMID 20814160 DOI: 10.2133/Dmpk.Dmpk-10-Nt-022  0.394
2010 Takano R, Murayama N, Horiuchi K, Kitajima M, Kumamoto M, Shono F, Yamazaki H. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling Regulatory Toxicology and Pharmacology. 58: 252-258. PMID 20600458 DOI: 10.1016/J.Yrtph.2010.06.008  0.312
2010 Ohtsuka T, Yoshikawa T, Kozakai K, Tsuneto Y, Uno Y, Utoh M, Yamazaki H, Kume T. Alprazolam as an In Vivo Probe for Studying Induction of CYP3A in Cynomolgus Monkeys Drug Metabolism and Disposition. 38: 1806-1813. PMID 20584745 DOI: 10.1124/Dmd.110.032656  0.357
2010 Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. British Journal of Clinical Pharmacology. 69: 593-7. PMID 20565450 DOI: 10.1111/J.1365-2125.2010.03656.X  0.358
2010 Uno Y, Uehara S, Kohara S, Murayama N, Yamazaki H. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan Drug Metabolism and Disposition. 38: 1486-1492. PMID 20501912 DOI: 10.1124/Dmd.110.033274  0.367
2010 Chowdhury G, Murayama N, Okada Y, Uno Y, Shimizu M, Shibata N, Guengerich FP, Yamazaki H. Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chemical Research in Toxicology. 23: 1018-24. PMID 20443640 DOI: 10.1021/Tx900367P  0.339
2010 Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Identification and Characterization of CYP2C18 in the Cynomolgus Macaque (Macaca fascicularis) Journal of Veterinary Medical Science. 72: 225-228. PMID 19940391 DOI: 10.1292/Jvms.09-0341  0.349
2010 Yamazaki H, Kuribayashi S, Inoue T, Tateno C, Nishikura Y, Oofusa K, Harada D, Naito S, Horie T, Ohta S. Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry. Chemical Research in Toxicology. 23: 152-158. PMID 19928966 DOI: 10.1021/Tx900323A  0.345
2010 Yamazaki H, Takano R, Horiuchi K, Shimizu M, Murayama N, Kitajima M, Shono F. Human Blood Concentrations of Dichlorodiphenyltrichloroethane (DDT) Extrapolated from Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling Journal of Health Science. 56: 566-575. DOI: 10.1248/Jhs.56.566  0.312
2010 Takano R, Murayama N, Horiuchi K, Kitajima M, Shono F, Yamazaki H. Blood Concentrations of 1,4-Dioxane in Humans after Oral Administration Extrapolated from In Vivo Rat Pharmacokinetics, In Vitro Human Metabolism, and Physiologically Based Pharmacokinetic Modeling Journal of Health Science. 56: 557-565. DOI: 10.1248/Jhs.56.557  0.311
2010 Niwa T, Murayama N, Yamazaki H. Comparison of the Contributions of Cytochromes P450 3A4 and 3A5 in Drug Oxidation Rates and Substrate Inhibition Journal of Health Science. 56: 239-256. DOI: 10.1248/Jhs.56.239  0.334
2009 Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). Journal of Veterinary Medical Science. 71: 1653-1656. PMID 20046035 DOI: 10.1292/Jvms.001653  0.358
2009 Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Cloning, Expression, and Characterization of CYP3A43 in Cynomolgus Macaque (Macaca fascicularis) Drug Metabolism Letters. 3: 228-233. PMID 20041831 DOI: 10.2174/187231209790218127  0.358
2009 Uno Y, Matsushita A, Osada N, Uehara S, Kohara S, Nagata R, Fukuzaki K, Utoh M, Murayama N, Yamazaki H. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 209-14. PMID 19910514 DOI: 10.1124/Dmd.109.029710  0.304
2009 Murai K, Yamazaki H, Nakagawa K, Kawai R, Kamataki T. Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 39: 795-802. PMID 19845430 DOI: 10.3109/00498250903171395  0.391
2009 Murayama N, Kaneko N, Horiuchi K, Ohyama K, Shimizu M, Ito K, Yamazaki H. Cytochrome P450-depedent Drug Oxidation Activity of Liver Microsomes from Microminipigs, A Possible New Animal Model for Humans in Non-clinical Studies Drug Metabolism and Pharmacokinetics. 24: 404-408. PMID 19745566 DOI: 10.2133/Dmpk.24.404  0.322
2009 Emoto C, Murayama N, Wakiya S, Yamazaki H. Effects of Histidine-Tag on Recombinant Human Cytochrome P450 3A5 Catalytic Activity in Reconstitution Systems Drug Metabolism Letters. 3: 207-211. PMID 19702542 DOI: 10.2174/187231209790218109  0.328
2009 Niwa T, Murayama N, Yamazaki H. Oxidation of Endobiotics Mediated by Xenobiotic-Metabolizing Forms of Human Cytochrome P450 Current Drug Metabolism. 10: 700-712. PMID 19594405 DOI: 10.2174/138920009789895525  0.358
2009 Nagashima S, Shimizu M, Yano H, Murayama N, Kumai T, Kobayashi S, Guengerich FP, Yamazaki H. Inter-individual Variation in Flavin-containing Monooxygenase 3 in Livers from Japanese: Correlation with Hepatic Transcription Factors Drug Metabolism and Pharmacokinetics. 24: 218-225. PMID 19571433 DOI: 10.2133/Dmpk.24.218  0.311
2009 Shimada T, Tanaka K, Takenaka S, Foroozesh MK, Murayama N, Yamazaki H, Guengerich FP, Komori M. Reverse type I binding spectra of human cytochrome P450 1B1 induced by flavonoid, stilbene, pyrene, naphthalene, phenanthrene, and biphenyl derivatives that inhibit catalytic activity: a structure-function relationship study. Chemical Research in Toxicology. 22: 1325-1333. PMID 19563207 DOI: 10.1021/Tx900127S  0.32
2009 Matsunaga M, Yamazaki H, Kiyotani K, Iwano S, Saruwatari J, Nakagawa K, Soyama A, Ozawa S, Sawada J, Kashiyama E, Kinoshita M, Kamataki T. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 699-701. PMID 19158312 DOI: 10.1124/Dmd.108.026096  0.312
2009 Kuribayashi S, Goto K, Naito S, Kamataki T, Yamazaki H. Human cytochrome P450 1A2 involvement in the formation of reactive metabolites from a species-specific hepatotoxic pyrazolopyrimidine derivative, 5-n-butyl-7-(3,4,5-trimethoxybenzoylamino)pyrazolo[1,5-a]pyrimidine. Chemical Research in Toxicology. 22: 323-331. PMID 19138062 DOI: 10.1021/Tx8003592  0.369
2009 Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, Yamazaki H. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. Drug Metabolism and Disposition. 37: 18-23. PMID 18948377 DOI: 10.1124/Dmd.108.024679  0.386
2008 Shimada T, Murajama N, Tanaka K, Takenaka S, Imai Y, Hopkins NE, Foroozesh MK, Alworth WL, Yamazaki H, Guengerich FP, Komori M. Interaction of polycyclic aromatic hydrocarbons with human cytochrome P450 1B1 in inhibiting catalytic activity. Chemical Research in Toxicology. 21: 2313-23. PMID 19548353 DOI: 10.1021/Tx8002998  0.318
2008 Emoto C, Murayama N, Yamazaki H. Effects of Enzyme Sources on Midazolam 1-Hydroxylation Activity Catalyzed by Recombinant Cytochrome P450 3A4 in Combination with NADPH-Cytochrome P450 Reductase Drug Metabolism Letters. 2: 190-192. PMID 19356092 DOI: 10.2174/187231208785425737  0.355
2008 Niwa T, Murayama N, Yamazaki H. Heterotropic Cooperativity in Oxidation Mediated by Cytochrome P450 Current Drug Metabolism. 9: 453-462. PMID 18537580 DOI: 10.2174/138920008784746364  0.365
2008 Fukami T, Katoh M, Yamazaki H, Yokoi T, Nakajima M. Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. Chemical Research in Toxicology. 21: 720-725. PMID 18266326 DOI: 10.1021/Tx700325F  0.34
2008 Yamazaki H, Niwa T, Murayama N, Emoto C. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Current Drug Metabolism. 9: 20-33. PMID 18220568 DOI: 10.2174/138920008783331121  0.361
2007 Shimizu M, Matsumoto Y, Yamazaki H. Effects of propofol analogs on glucuronidation of propofol, an anesthetic drug, by human liver microsomes. Drug Metabolism Letters. 1: 77-79. PMID 19356023 DOI: 10.2174/187231207779814355  0.316
2007 Murayama N, Minoshima M, Shimizu M, Guengerich FP, Yamazaki H. Involvement of human cytochrome P450 2B6 in the ω- and 4-hydroxylation of the anesthetic agent propofol Xenobiotica. 37: 717-724. PMID 17620218 DOI: 10.1080/00498250701449431  0.382
2007 Perrett H, Barter Z, Jones B, Yamazaki H, Tucker G, Rostami-Hodjegan A. Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes Drug Metabolism and Disposition. 35: 1733-1736. PMID 17600083 DOI: 10.1124/Dmd.107.015743  0.354
2007 Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes Biochemical Pharmacology. 73: 2020-2026. PMID 17433262 DOI: 10.1016/J.Bcp.2007.03.012  0.35
2007 Shimada T, Murayama N, Okada K, Funae Y, Yamazaki H, Guengerich FP. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chemical Research in Toxicology. 20: 489-496. PMID 17291012 DOI: 10.1021/Tx600299P  0.321
2006 Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K. In vivo Evaluation of Coumarin and Nicotine as Probe Drugs to Predict the Metabolic Capacity of CYP2A6 Due to Genetic Polymorphism in Thais Drug Metabolism and Pharmacokinetics. 21: 475-484. PMID 17220563 DOI: 10.2133/Dmpk.21.475  0.301
2006 Nakajima M, Itoh M, Sakai H, Fukami T, Katoh M, Yamazaki H, Kadlubar FF, Imaoka S, Funae Y, Yokoi T. CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. International Journal of Cancer. 119: 2520-6. PMID 16988941 DOI: 10.1002/Ijc.22136  0.339
2006 Yamazaki H, Shimizu M, Nagashima T, Minoshima M, Murayama N. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metabolism and Disposition. 34: 1803-1805. PMID 16896062 DOI: 10.1124/Dmd.106.011627  0.344
2006 Inoue S, Howgate EM, Rowland-Yeo K, Shimada T, Yamazaki H, Tucker GT, Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences Xenobiotica. 36: 499-513. PMID 16865818 DOI: 10.1080/00498250600683262  0.311
2006 Saito M, Okutomi T, Shimizu M, Matsumoto Y, Yamazaki H, Hoka S. Activities of rat cytochrome P450 3A and 2C isoforms are increased in vivo by magnesium sulfate as evidenced by enhanced oxidation of bupivacaine and testosterone in liver microsomes. Drug Metabolism and Pharmacokinetics. 21: 201-207. PMID 16858123 DOI: 10.2133/Dmpk.21.201  0.358
2006 Kuribayashi S, Ueda N, Naito S, Yamazaki H, Kamataki T. Species differences in hydrolase activities toward OT-7100 responsible for different bioavailability in rats, dogs, monkeys and humans. Xenobiotica. 36: 301-314. PMID 16684710 DOI: 10.1080/00498250600571798  0.31
2005 Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, Nakagawa K, Ishizaki T, Kamataki T. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metabolism and Disposition. 33: 1361-1366. PMID 15980104 DOI: 10.1124/Dmd.105.004796  0.339
2005 Miyazaki M, Sugawara E, Yoshimura T, Yamazaki H, Kamataki T. Mutagenic activation of betel quid-specific N-nitrosamines catalyzed by human cytochrome P450 coexpressed with NADPH-cytochrome P450 reductase in Salmonella typhimurium YG7108. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 581: 165-171. PMID 15725615 DOI: 10.1016/J.Mrgentox.2004.12.002  0.36
2004 Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T. CYP3A5 Contributes Significantly to CYP3A-mediated Drug Oxidations in Liver Microsomes from Japanese Subjects Drug Metabolism and Pharmacokinetics. 19: 120-129. PMID 15499178 DOI: 10.2133/Dmpk.19.120  0.346
2004 Yamazaki Y, Fujita K, Nakayama K, Suzuki A, Nakamura K, Yamazaki H, Kamataki T. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 562: 151-162. PMID 15279838 DOI: 10.1016/J.Mrgentox.2004.06.003  0.355
2004 Toide K, Terauchi Y, Fujii T, Yamazaki H, Kamataki T. Uridine diphosphate sugar-selective conjugation of an aldose reductase inhibitor (AS-3201) by UDP-glucuronosyltransferase 2B subfamily in human liver microsomes. Biochemical Pharmacology. 67: 1269-1278. PMID 15013842 DOI: 10.1016/J.Bcp.2003.11.010  0.334
2004 Matsumura K, Saito T, Takahashi Y, Ozeki T, Kiyotani K, Fujieda M, Yamazaki H, Kunitoh H, Kamataki T. Identification of a Novel Polymorphic Enhancer of the Human CYP3A4 Gene Molecular Pharmacology. 65: 326-334. PMID 14742674 DOI: 10.1124/Mol.65.2.326  0.317
2003 Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita Ki, Kamataki T. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochemical Pharmacology. 66: 2333-40. PMID 14637191 DOI: 10.1016/J.Bcp.2003.08.004  0.34
2003 Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, Ujjin P, Shimada T, Guengerich FP, Parkinson A, Honda G, Nakagawa K, Ishizaki T, Kamataki T. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics. 13: 689-695. PMID 14583682 DOI: 10.1097/00008571-200311000-00005  0.343
2003 Takemoto K, Yamazaki H, Tanaka Y, Nakajima M, Yokoi T. Catalytic activities of cytochrome P450 enzymes and UDP-glucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica. 33: 43-55. PMID 12519693 DOI: 10.1080/0049825021000022348  0.324
2002 Yamazaki H, Iketaki H, Shibata A, Nakajima M, Yokoi T. Activities of Cytochrome P450 Enzymes in Liver and Kidney Microsomes from Systemic Carnitine Deficiency Mice with a Gene Mutation of Carnitine/Organic Cation Transporter Drug Metabolism and Pharmacokinetics. 17: 47-53. PMID 15618652 DOI: 10.2133/Dmpk.17.47  0.341
2002 Saruwatari J, Nakagawa K, Shindo J, Tajiri T, Fujieda M, Yamazaki H, Kamataki T, Ishizaki T. A population phenotyping study of three drug‐metabolizing enzymes in Kyushu, Japan, with use of the caffeine test Clinical Pharmacology & Therapeutics. 72: 200-208. PMID 12189367 DOI: 10.1067/Mcp.2002.126173  0.334
2002 Takemoto K, Yamazaki H, Nakajima M, Yokoi T. Genotoxic activation of benzophenone and its two metabolites by human cytochrome P450s in SOS/umu assay Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 519: 199-204. PMID 12160905 DOI: 10.1016/S1383-5718(02)00141-9  0.361
2002 Komatsu T, Yamazaki H, Nakajima M, Yokoi T. Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes. Biochemical Pharmacology. 63: 2081-2090. PMID 12110367 DOI: 10.1016/S0006-2952(02)01024-9  0.367
2002 Yamazaki H, Kamataki T. P450 and carcinogenesis Folia Pharmacologica Japonica. 119: 208-212. PMID 11979725 DOI: 10.1254/Fpj.119.208  0.355
2002 Nakajima M, Tane K, Nakamura S, Shimada N, Yamazaki H, Yokoi T. Evaluation of Approach to Predict the Contribution of Multiple Cytochrome P450s in Drug Metabolism Using Relative Activity Factor: Effects of the Differences in Expression Levels of NADPH–Cytochrome P450 Reductase and Cytochrome b5 in the Expression System and the Differences in the Marker Activities Journal of Pharmaceutical Sciences. 91: 952-963. PMID 11948533 DOI: 10.1002/Jps.10091  0.344
2002 Ujjin P, Satarug S, Vanavanitkun Y, Daigo S, Ariyoshi N, Yamazaki H, Reilly PEB, Moore MR, Kamataki T. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Pharmacogenetics. 12: 241-249. PMID 11927840 DOI: 10.1097/00008571-200204000-00009  0.308
2002 Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, Yokoi T. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression and Purification. 24: 329-337. PMID 11922748 DOI: 10.1006/Prep.2001.1578  0.329
2001 Hatanaka N, Yamazaki H, Kizu R, Hayakawa K, Aoki Y, Iwanari M, Nakajima M, Yokoi T. Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust Carcinogenesis. 22: 2033-2038. PMID 11751436 DOI: 10.1093/Carcin/22.12.2033  0.341
2001 Hatanaka N, Yamazaki H, Oda Y, Guengerich FP, Nakajima M, Yokoi T. Metabolic activation of carcinogenic 1-nitropyrene by human cytochrome P450 1B1 in Salmonella typhimurium strain expressing an O-acetyltransferase in SOS/umu assay Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 497: 223-233. PMID 11525925 DOI: 10.1016/S1383-5718(01)00254-6  0.321
2001 Emoto C, Yamazaki H, Iketaki H, Yamasaki S, Satoh T, Shimizu R, Suzuki S, Shimada N, Nakajima M, Yokoi T. Cooperativity of α-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human Xenobiotica. 31: 265-275. PMID 11491388 DOI: 10.1080/00498250110052120  0.325
2001 Kwon J, Nakajima M, Chai S, Yom Y, Kim H, Yamazaki H, Sohn D, Yamamoto T, Kuroiwa Y, Yokoi T. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics. 11: 317-323. PMID 11434509 DOI: 10.1097/00008571-200106000-00006  0.301
2001 Shimada T, Tsumura F, Yamazaki H, Guengerich F, Inoue K. Characterization of (±)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for cyp2d6 Pharmacogenetics. 11: 143-156. PMID 11266079 DOI: 10.1097/00008571-200103000-00005  0.302
2001 Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. European Journal of Pharmaceutical Sciences. 12: 505-513. PMID 11231118 DOI: 10.1016/S0928-0987(00)00215-3  0.308
2001 Nakajima M, Kwon J, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H, Yamazaki H, Yamamoto T, Kuroiwa Y, Yokoi T. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans Clinical Pharmacology & Therapeutics. 69: 72-78. PMID 11180041 DOI: 10.1067/Mcp.2001.112688  0.306
2001 Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions British Journal of Clinical Pharmacology. 49: 244-253. PMID 10718780 DOI: 10.1046/J.1365-2125.2000.00134.X  0.337
2000 Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. Use of everted sacs of mouse small intestine as enzyme sources for the study of drug oxidation activities in vitro. Xenobiotica. 30: 971-982. PMID 11315105 DOI: 10.1080/00498250050200122  0.306
2000 Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica. 30: 943-953. PMID 11315103 DOI: 10.1080/00498250050200104  0.34
2000 Yamazaki H. ヒトチトクロム P450 の薬物代謝学・毒性学的研究 Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan. 120: 1347-1357. PMID 11193384 DOI: 10.1248/Yakushi1947.120.12_1347  0.371
2000 Yamazaki H, Hatanaka N, Kizu R, Hayakawa K, Shimada N, Guengerich FP, Nakajima M, Yokoi T. Bioactivation of diesel exhaust particle extracts and their major nitrated polycyclic aromatic hydrocarbon components, 1-nitropyrene and dinitropyrenes, by human cytochromes P450 1A1, 1A2, and 1B1. Mutation Research-Genetic Toxicology and Environmental Mutagenesis. 472: 129-138. PMID 11113705 DOI: 10.1016/S1383-5718(00)00138-8  0.326
2000 Inoue K, Yamazaki H, Shimada T. Characterization of liver microsomal 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene. Archives of Toxicology. 74: 372-378. PMID 11043492 DOI: 10.1007/S002040000151  0.318
2000 Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions European Journal of Clinical Pharmacology. 55: 843-852. PMID 10805063 DOI: 10.1007/S002280050706  0.33
2000 Inoue K, Yamazaki H, Shimada T. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians. Archives of Toxicology. 73: 532-539. PMID 10663384 DOI: 10.1007/S002040050005  0.318
2000 Yamazaki H, Suzuki M, Tane K, Shimada N, Nakajima M, Yokoi T. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica. 30: 61-70. PMID 10659951 DOI: 10.1080/004982500237820  0.356
2000 Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K. Relationships Between Genetic Polymorphisms In Cyp2D6 And Cyp2E1 Genes And Liver Microsomal Drug Oxidation Activities Drug Metabolism and Pharmacokinetics. 15: 84-85. DOI: 10.2133/Dmpk.15.Supplement_84  0.344
1999 Nakajima M, Suzuki M, Yamaji R, Takashina H, Shimada N, Yamazaki H, Yokoi T. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica. 29: 1191-1202. PMID 10647906 DOI: 10.1080/004982599237877  0.316
1999 Yun C, Ahn T, Guengerich FP, Yamazaki H, Shimada T. Phospholipase D activity of cytochrome P450 in human liver endoplasmic reticulum. Archives of Biochemistry and Biophysics. 367: 81-88. PMID 10375402 DOI: 10.1006/Abbi.1999.1254  0.361
1999 Yamazaki H, Inoue K, Hashimoto M, Shimada T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology. 73: 65-70. PMID 10350185 DOI: 10.1007/S002040050588  0.348
1999 Yamazaki H, Tanaka M, Shimada T. Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. Journal of Chromatography B: Biomedical Sciences and Applications. 721: 13-19. PMID 10027632 DOI: 10.1016/S0378-4347(98)00472-1  0.346
1999 Shimada T, Inoue K, Yamazaki H. Variations in contents of liver microsomal cytochrome P450 isofoms and activities of drug oxidations in humans Drug Metabolism and Pharmacokinetics. 14: 78-79. DOI: 10.2133/Dmpk.14.Supplement_78  0.383
1999 Yamazaki H, Nakajima M, Shimada N, Yokoi T. Roles Of Human P450 Enzymes In Drug Oxidations Using Recombinant P450S And Human Liver Microsomes Drug Metabolism and Pharmacokinetics. 14: 76-77. DOI: 10.2133/Dmpk.14.Supplement_76  0.38
1998 Yamazaki H, Shimada T. Cytochrome P450 reconstitution systems. Methods of Molecular Biology. 320: 61-71. PMID 16719374 DOI: 10.1385/1-59259-998-2:61  0.372
1998 Ueng Y, Shimada T, Yamazaki H, Peterguengerich F. AFLATOXIN B1 OXIDATION BY HUMAN CYTOCHROME P450s Journal of Toxicological Sciences. 23: 132-135. PMID 9760449 DOI: 10.2131/Jts.23.Supplementii_132  0.302
1998 Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology. 56: 243-51. PMID 9698079 DOI: 10.1016/S0006-2952(98)00133-6  0.365
1998 Guengerich FP, Johnson WW, Shimada T, Ueng Y, Yamazaki H, Langouët S. Activation and detoxication of aflatoxin B1 Mutation Research. 402: 121-128. PMID 9675258 DOI: 10.1016/S0027-5107(97)00289-3  0.374
1998 Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chemical Research in Toxicology. 11: 659-65. PMID 9625734 DOI: 10.1021/Tx970217F  0.353
1998 Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes Xenobiotica. 28: 103-115. PMID 9522436 DOI: 10.1080/004982598239614  0.348
1998 Yamazaki H. The characteristic of human CYP3A4 catalytic activity. Drug Metabolism and Pharmacokinetics. 13: 572-573. DOI: 10.2133/Dmpk.13.572  0.308
1997 Yamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochemical Pharmacology. 54: 1195-1203. PMID 9416970 DOI: 10.1016/S0006-2952(97)00304-3  0.313
1997 Yamazaki H, Shimada T. Progesterone and Testosterone Hydroxylation by Cytochromes P450 2C19, 2C9, and 3A4 in Human Liver Microsomes Archives of Biochemistry and Biophysics. 346: 161-169. PMID 9328296 DOI: 10.1006/Abbi.1997.0302  0.375
1997 Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, Yamazaki H. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans Archives of Toxicology. 71: 401-408. PMID 9195021 DOI: 10.1007/S002040050403  0.387
1997 Yamazaki H, Gillam EMJ, Dong M, Johnson WW, Guengerich FP, Shimada T. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions. Archives of Biochemistry and Biophysics. 342: 329-337. PMID 9186495 DOI: 10.1006/Abbi.1997.0125  0.335
1997 Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics. 7: 103-113. PMID 9170147 DOI: 10.1097/00008571-199704000-00003  0.332
1997 Guengerich FP, Ueng YF, Kim BR, Langouet S, Coles B, Iyer RS, Thier R, Harris TM, Shimada T, Yamazaki H, Ketterer B, Guillouzo A. Activation of toxic chemicals by cytochrome P450 enzymes: regio- and stereoselective oxidation of aflatoxin B1. Advances in Experimental Medicine and Biology. 387: 7-15. PMID 8794188 DOI: 10.1007/978-1-4757-9480-9_2  0.307
1997 Shimada T, Inoue K, Shaw PM, Guengerich FP, Yamazaki H. Omeprazole Hydroxylation By Cyp2C19 And Cyp3A4: Prediction Towards Human Liver Activities Using The Data Of Recombinant P450 Enzymes Drug Metabolism and Pharmacokinetics. 12: 120-121. DOI: 10.2133/Dmpk.12.Supplement_120  0.367
1996 Hou Z, Fujita A, Yoshimura T, Jesorka A, Zhang Y, Yamazaki H, Wakatsuki Y. Heteroleptic Lanthanide Complexes with Aryloxide Ligands. Synthesis and Structural Characterization of Divalent and Trivalent Samarium Aryloxide/Halide and Aryloxide/Cyclopentadienide Complexes. Inorganic Chemistry. 35: 7190-7195. PMID 11666906 DOI: 10.1021/Ic960683C  0.31
1996 Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations Xenobiotica. 26: 395-403. PMID 9173680 DOI: 10.3109/00498259609046718  0.327
1996 Yamazaki H, Urano T, Hiroki S, Shimada T. Effects of erythromycin and roxithromycin on oxidation of testosterone and nifedipine catalyzed by CYP3A4 in human liver microsomes. Journal of Toxicological Sciences. 21: 215-226. PMID 8959645 DOI: 10.2131/Jts.21.4_215  0.37
1996 Yamazaki H, Hiroki S, Urano T, Inoue K, Shimada T. Effects of roxithromycin, erythromycin and troleandomycin on their N-demethylation by rat and human cytochrome P450 enzymes Xenobiotica. 26: 1143-1153. PMID 8948090 DOI: 10.3109/00498259609050259  0.312
1996 Yamazaki H, Johnson WW, Ueng Y, Shimada T, Guengerich FP. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. Journal of Biological Chemistry. 271: 27438-27444. PMID 8910324 DOI: 10.1074/Jbc.271.44.27438  0.334
1996 Guengerich FP, Johnson WW, Ueng YF, Yamazaki H, Shimada T. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environmental Health Perspectives. 104: 557-562. PMID 8781383 DOI: 10.1289/Ehp.96104S3557  0.374
1996 Yamazaki H, Nakano M, Gillam EM, Bell LC, Guengerich FP, Shimada T. Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes. Biochemical Pharmacology. 52: 301-9. PMID 8694855 DOI: 10.1016/0006-2952(96)00208-0  0.343
1996 Dong M, Yamazaki H, Guo Z, Guengerich FP. Recombinant human cytochrome P450 1A2 and an N-terminal-truncated form: construction, purification, aggregation properties, and interactions with flavodoxin, ferredoxin, and NADPH-cytochrome P450 reductase. Archives of Biochemistry and Biophysics. 327: 11-19. PMID 8615680 DOI: 10.1006/Abbi.1996.0086  0.35
1996 Yamazaki H, Nakano M, Imai Y, Ueng Y, Guengerich FP, Shimada T. Roles of Cytochrome b5in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes Archives of Biochemistry and Biophysics. 325: 174-182. PMID 8561495 DOI: 10.1006/Abbi.1996.0022  0.37
1996 Koehl W, Amin S, Yamazaki H, Ueng Y, Tateishi T, Guengerich FP, Hecht SS. Metabolic Activation of Chrysene by Human Hepatic and Pulmonary Cytochrome P450 Enzymes Polycyclic Aromatic Compounds. 10: 59-66. DOI: 10.1080/10406639608034680  0.36
1995 Gillam EMJ, Guo Z, Ueng Y, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP. Expression of Cytochrome-P450-3A5 in Escherichia Coli: Effects of 5′ Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities Archives of Biochemistry and Biophysics. 317: 374-384. PMID 7893152 DOI: 10.1006/Abbi.1995.1177  0.325
1995 Ueng Y, Shimada T, Yamazaki H, Guengerich FP. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chemical Research in Toxicology. 8: 218-225. PMID 7766804 DOI: 10.1021/Tx00044A006  0.357
1995 Guengerich FP, Shimada T, Yun CH, Yamazaki H, Raney KD, Thier R, Coles B, Harris TM. Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environmental Health Perspectives. 49-53. PMID 7698084 DOI: 10.1289/Ehp.94102S949  0.322
1995 Yamazaki H, Ueng Y, Shimada T, Guengerich FP. Roles of Divalent Metal Ions in Oxidations Catalyzed by Recombinant Cytochrome P450 3A4 and Replacement of NADPH-Cytochrome P450 Reductase with Other Flavoproteins, Ferredoxin, and Oxygen Surrogates Biochemistry. 34: 8380-8389. PMID 7599128 DOI: 10.1021/Bi00026A020  0.343
1995 Shimada T, Yamazaki H, Guengerich FP. Metabolic Activation of Procarcinogens by Human Cytochrome P450 Enzymes in Microsomes of Adult and Fetal Livers and of Adult Lungs Drug Metabolism and Pharmacokinetics. 10: 126-129. DOI: 10.2133/Dmpk.10.Supplement_126  0.358
1995 Gillam E, Guo Z, Ueng Y, Yamazaki H, Cock I, Reilly P, Hooper W, Guengerich F. Expression of Cytochrome-P450-3A5 in Escherichia-Coli - Effects of 5' Modification, Purification, Spectral Characterization, Reconstitution Conditions, and Catalytic Activities (Vol 317, Pg 374, 1995) Archives of Biochemistry and Biophysics. 318: 498-498. DOI: 10.1006/Abbi.1995.1259  0.323
1994 Yamazaki H, Mimura M, Oda Y, Gonzalez FJ, el-Bayoumy K, Chae YH, Guengerich FP, Shimada T. Activation of trans-1,2-dihydro-1,2-dihydroxy-6-aminochrysene to genotoxic metabolites by rat and human cytochromes P450. Carcinogenesis. 15: 465-70. PMID 8118930 DOI: 10.1093/Carcin/15.3.465  0.336
1994 Yamazaki H, Mimura M, Sugahara C, Shimada T. Catalytic roles of rat and human cytochrome P450 2A enzymes in testosterone 7α- and coumarin 7-hydroxylations Biochemical Pharmacology. 48: 1524-1527. PMID 7945454 DOI: 10.1016/0006-2952(94)90579-7  0.36
1994 Mimura M, Yamazaki H, Sugahara C, Hiroi T, Funae Y, Shimada T. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes Biochemical Pharmacology. 47: 1957-1963. PMID 7912070 DOI: 10.1016/0006-2952(94)90069-8  0.367
1994 Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, Shimada T, Funae Y. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochemical Pharmacology. 47: 727-735. PMID 7510480 DOI: 10.1016/0006-2952(94)90136-8  0.377
1993 Yamazaki H, Mimura M, Oda Y, Inui Y, Shiraga T, Iwasaki K, Guengerich FP, Shimada T. Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochrysene to genotoxic metabolites in human liver microsomes. Carcinogenesis. 14: 1271-8. PMID 8330339 DOI: 10.1093/Carcin/14.7.1271  0.36
1992 Yamazaki H, Oda Y, Funae Y, Imaoka S, Inui Y, Guengerich FP, Shimada T. Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis. 13: 979-85. PMID 1600620 DOI: 10.1093/Carcin/13.6.979  0.336
1992 Yamazaki H, Inui Y, Yun C, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes Carcinogenesis. 13: 1789-1794. PMID 1423839 DOI: 10.1093/Carcin/13.10.1789  0.376
1992 Yamazaki H, Oda Y, Shimada T. Use of a newly developed tester strain Salmonella typhimurium NM2009 for the study of metabolic activation of carcinogenic aromatic amines by rat liver microsomal cytochrome P-450 enzymes. Mutation Research\/Environmental Mutagenesis and Related Subjects. 272: 183-192. PMID 1383750 DOI: 10.1016/0165-1161(92)90046-O  0.31
1992 Shimada T, Yamazaki H, Mimura M, Guengerich FP. Rat pulmonary microsomal cytochrome P-450 enzymes involved in the activation of procarcinogens. Mutation Research. 284: 233-241. PMID 1281274 DOI: 10.1016/0027-5107(92)90007-O  0.332
1992 Yamashita N, Shimada T, Tanabe S, Yamazaki H, Tatsukawa R. Cytochrome P-450 forms and its inducibility by PCB isomers in black-headed gulls and black-tailed gulls Marine Pollution Bulletin. 24: 316-321. DOI: 10.1016/0025-326X(92)90593-U  0.349
1991 Yamazaki H, Degawa M, Funae Y, Imaoka S, Inui Y, Guengerich FP, Shimada T. Roles of different cytochrome P450 enzymes in bioactivation of the potent hepatocarcinogen 3-methoxy-4-aminoazobenzene by rat and human liver microsomes. Carcinogenesis. 12: 133-9. PMID 1988174 DOI: 10.1093/Carcin/12.1.133  0.348
1991 Aoki K, Ninghai H, Yamazaki H. X-ray studies on metal ion interactions with vitamins II. Crystal structures of three copper(II) and nickel(II) complexes of Schiff bases formed between 1-aminocyclopropanecarboxylic acid and pyridoxal or pyridoxal 5′-phosphate Inorganica Chimica Acta. 186: 253-261. DOI: 10.1016/S0020-1693(00)85430-4  0.31
1991 Hong P, Mise T, Yamazaki H. Rhodium carbonyl-catalyzed carbonylation of unsaturated compounds: V. Cross-hydrocarbonylation of 1-alkyne and ethylen by rhodium carbonyl catalyst modified with phosphines Journal of Organometallic Chemistry. 412: 291-300. DOI: 10.1016/0022-328X(91)86063-V  0.301
1990 Shimada T, Yamazaki H, Shimura H, Tanaka R, Guengerich FP. Metabolic deactivation of furylfuramide by cytothrome P450 in human and liver microsomes Carcinogenesis. 11: 103-110. PMID 2403855 DOI: 10.1093/Carcin/11.1.103  0.36
1989 Yamamoto Y, Yamazaki H. Low-valent isocyanide complexes and clusters of palladium and platinum. Crystal structure of [Pt{C(NR)N(R)C(NR}(RNC)2](R = 2,6-Me2C6H3) Journal of the Chemical Society-Dalton Transactions. 2161-2166. DOI: 10.1039/Dt9890002161  0.302
1985 Mori Y, Yamazaki H, Toyoshi K, Makino T, Obara T, Yokose Y, Konishi Y. Mutagenic activation of carcinogenic N-nitrosopropylamines by rat liver: evidence for a cytochrome P-450 dependent reaction Carcinogenesis. 6: 415-420. PMID 3884171 DOI: 10.1093/Carcin/6.3.415  0.321
1984 Mori Y, Niwa T, Yamazaki H, Nii H, Toyoshi K, Hirano K, Sugiura M. Influence of Microsomal and Cytosolic Fractions from the Liver of 4 Animal Species and Man on the Mutagenicity of Carcinogenic Aminoazo Dyes and Nature of the Mutagenicity-Enhancing Factor in the Cytosol from Rat Liver Chemical & Pharmaceutical Bulletin. 32: 3641-3650. PMID 6441646 DOI: 10.1248/Cpb.32.3641  0.302
1970 Yamamoto Y, Yamazaki H. Studies on interactions of isocyanides with transition metal complexes Journal of Organometallic Chemistry. 24: 717-724. DOI: 10.1016/S0022-328X(00)84504-0  0.315
Show low-probability matches.